Nothing Special   »   [go: up one dir, main page]

MA39449A1 - Procédé d'obtention d'énantiomères de pirlindole optiquement actifs et de sels de ceux-ci - Google Patents

Procédé d'obtention d'énantiomères de pirlindole optiquement actifs et de sels de ceux-ci

Info

Publication number
MA39449A1
MA39449A1 MA39449A MA39449A MA39449A1 MA 39449 A1 MA39449 A1 MA 39449A1 MA 39449 A MA39449 A MA 39449A MA 39449 A MA39449 A MA 39449A MA 39449 A1 MA39449 A1 MA 39449A1
Authority
MA
Morocco
Prior art keywords
optically active
salts
obtaining enantiomers
pirlindole
active pirlindole
Prior art date
Application number
MA39449A
Other languages
English (en)
Inventor
Filipe Augusto Eugénio Pardal
Pedroso Pedro Filipe Eufrásio
Pecorelli Susana Marques Almeida
Caixado Carlos Alberto Eufrásio Casimiro
Ana Sofia Da Conceição Lopes
João Carlos Ramos Damil
Oliveira Santos Pedro Paulo De Lacerda E
Original Assignee
Tecnimede Soc Tecnico-Medicinal S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc Tecnico-Medicinal S A filed Critical Tecnimede Soc Tecnico-Medicinal S A
Publication of MA39449A1 publication Critical patent/MA39449A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00Separation of optically-active compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne un nouveau procédé d'obtention d'énantiomères de pirlindole optiquement actifs, sous forme d'une base libre ou sous forme de sels pharmaceutiquement acceptables. Les produits obtenus selon la présente invention sont énantiomériquement purs et sont utiles en médecine.
MA39449A 2014-05-09 2014-05-09 Procédé d'obtention d'énantiomères de pirlindole optiquement actifs et de sels de ceux-ci MA39449A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000027 WO2015171003A1 (fr) 2014-05-09 2014-05-09 Procédé d'obtention d'énantiomères de pirlindole optiquement actifs et de sels de ceux-ci

Publications (1)

Publication Number Publication Date
MA39449A1 true MA39449A1 (fr) 2017-11-30

Family

ID=50819929

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39449A MA39449A1 (fr) 2014-05-09 2014-05-09 Procédé d'obtention d'énantiomères de pirlindole optiquement actifs et de sels de ceux-ci

Country Status (30)

Country Link
US (1) US9682986B2 (fr)
EP (1) EP3140265B1 (fr)
JP (1) JP6516769B2 (fr)
KR (1) KR102258709B1 (fr)
CN (1) CN106414376B (fr)
AU (1) AU2014393488C1 (fr)
BR (1) BR112016025918B1 (fr)
CA (1) CA2948604C (fr)
CY (1) CY1122367T1 (fr)
DK (1) DK3140265T3 (fr)
EC (1) ECSP16086217A (fr)
ES (1) ES2753403T3 (fr)
HR (1) HRP20192029T1 (fr)
HU (1) HUE046437T2 (fr)
IL (1) IL248853B (fr)
LT (1) LT3140265T (fr)
MA (1) MA39449A1 (fr)
MX (1) MX357918B (fr)
NZ (1) NZ726129A (fr)
PH (1) PH12016502234A1 (fr)
PL (1) PL3140265T3 (fr)
PT (1) PT3140265T (fr)
RS (1) RS59499B1 (fr)
RU (1) RU2666731C2 (fr)
SA (1) SA516380265B1 (fr)
SI (1) SI3140265T1 (fr)
TN (1) TN2016000496A1 (fr)
UA (1) UA118696C2 (fr)
WO (1) WO2015171003A1 (fr)
ZA (1) ZA201607722B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59499B1 (sr) 2014-05-09 2019-12-31 Tecnimede Sociedade Tecnico Medicinal S A Proces za dobijanje optički aktivnih enantiomera pirlindola i njihovih soli
DK3831385T3 (da) * 2014-05-09 2024-08-26 Tecnimede Sociedade Tecnico Medicinal S Mandelatsalte af pirlindol-enantiomerer til anvendelse i medicin
EP3392251A1 (fr) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation des enantiomères de pirlindole et leurs sels
EP3392250A1 (fr) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Procedé pour la préparation de l'anneau de pipérazine pour la synthèse de pyrazinocarbazole

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2281085C2 (ru) * 2004-05-25 2006-08-10 Закрытое акционерное общество "Мастерлек" Антидепрессивные лекарственные средства для парентерального применения на основе сульфонатных солей пирлиндола
RS59499B1 (sr) 2014-05-09 2019-12-31 Tecnimede Sociedade Tecnico Medicinal S A Proces za dobijanje optički aktivnih enantiomera pirlindola i njihovih soli

Also Published As

Publication number Publication date
ES2753403T3 (es) 2020-04-08
WO2015171003A1 (fr) 2015-11-12
SA516380265B1 (ar) 2019-11-04
AU2014393488A1 (en) 2016-11-24
EP3140265B1 (fr) 2019-08-28
HRP20192029T1 (hr) 2020-02-07
JP6516769B2 (ja) 2019-05-22
IL248853B (en) 2020-01-30
PH12016502234B1 (en) 2017-01-09
CY1122367T1 (el) 2021-01-27
LT3140265T (lt) 2019-12-10
TN2016000496A1 (en) 2018-04-04
NZ726129A (en) 2019-03-29
UA118696C2 (uk) 2019-02-25
EP3140265A1 (fr) 2017-03-15
KR20170004995A (ko) 2017-01-11
PT3140265T (pt) 2019-12-02
CN106414376A (zh) 2017-02-15
US20170145024A1 (en) 2017-05-25
CA2948604C (fr) 2021-06-15
RU2016148181A3 (fr) 2018-06-13
AU2014393488B2 (en) 2018-11-08
DK3140265T3 (da) 2019-11-18
AU2014393488C1 (en) 2020-07-16
BR112016025918B1 (pt) 2023-05-16
CA2948604A1 (fr) 2015-11-12
KR102258709B1 (ko) 2021-06-01
US9682986B2 (en) 2017-06-20
MX2016014703A (es) 2017-05-23
BR112016025918A2 (fr) 2017-08-15
PH12016502234A1 (en) 2017-01-09
CN106414376B (zh) 2019-06-07
RU2016148181A (ru) 2018-06-13
HUE046437T2 (hu) 2020-03-30
IL248853A0 (en) 2017-01-31
RU2666731C2 (ru) 2018-09-12
JP2017514883A (ja) 2017-06-08
ECSP16086217A (es) 2017-02-24
RS59499B1 (sr) 2019-12-31
SI3140265T1 (sl) 2019-12-31
PL3140265T3 (pl) 2020-02-28
MX357918B (es) 2018-07-30
ZA201607722B (en) 2022-05-25

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
CR20130629A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
MX2019000536A (es) Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX2015001917A (es) Composiciones farmaceuticas de memantina.
MX2018004664A (es) Antagonistas de ep4.
EP4249071A3 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA39449A1 (fr) Procédé d'obtention d'énantiomères de pirlindole optiquement actifs et de sels de ceux-ci
DOP2018000103A (es) Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para tratar enfermedad de parkinson.
EA201790315A1 (ru) Модуляторы x-рецепторов печени
PH12015502676A1 (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
PH12016502235A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
PH12016502527A1 (en) Stabilized desmopressin
PH12020500385A1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof
FR3028760B1 (fr) Composition cosmetique de soin et/ou de maquillage de la peau
PE20170522A1 (es) Forma polimorfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzheimer
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6